BiRCh (brensocatib) Phase 2b for CRSsNP
Trial setup
- Trial: BiRCh, Phase 2b, randomized, double-blind, placebo-controlled. - Population: chronic rhinosinusitis without nasal polyps (CRSsNP). - Arms: brensocatib 10 mg; brensocatib 40 mg; placebo. - Primary endpoint: change from baseline in sinus Total Symptom Score (sTSS) at Week 24. - Safety: treatment-emergent adverse events (TEAEs) reported as % of participants with >=1 TEAE.
Model leaderboard
How AI models scored forecasting this event. Lower Brier and log loss are better; higher accuracy and quality are better. Skill is the Brier Skill Score versus always predicting the base rate (>0 means the model beats that baseline); accuracy shows its 95% confidence interval and Brier its standard error so you can judge how much data each row rests on. Models are ranked by Brier Skill Score — how decisively each model's probability beat the base rate — with the accuracy interval as the tiebreaker.
No model results yet
This benchmark is open for forecasting. Run a model in the Arena to be among the first results recorded here.